AR024438A1 - GONADOTROPINE HORMONAL LIBERATING ANTAGONIST - Google Patents

GONADOTROPINE HORMONAL LIBERATING ANTAGONIST

Info

Publication number
AR024438A1
AR024438A1 ARP000103116A ARP000103116A AR024438A1 AR 024438 A1 AR024438 A1 AR 024438A1 AR P000103116 A ARP000103116 A AR P000103116A AR P000103116 A ARP000103116 A AR P000103116A AR 024438 A1 AR024438 A1 AR 024438A1
Authority
AR
Argentina
Prior art keywords
hormonal
gonadotropine
liberating
antagonist
administration
Prior art date
Application number
ARP000103116A
Other languages
Spanish (es)
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of AR024438A1 publication Critical patent/AR024438A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un método para prevenir un aumento prematuro de HL. El método emplea la administracion del antagonista hormonal liberador de gonadotropina ganirelix en unacantidad dependiente del peso corporal de la paciente. El método se puede emplear en combinacion con la administracion de FSH exogeno en el tratamiento demujeres que sufren de hiperovulacion controlada.A method to prevent a premature increase in HL. The method employs the administration of the hormonal antagonist releasing gonadotropin ganirelix in a quantity dependent on the patient's body weight. The method can be used in combination with the administration of exogenous FSH in the treatment of women suffering from controlled hyperovulation.

ARP000103116A 1999-06-23 2000-06-22 GONADOTROPINE HORMONAL LIBERATING ANTAGONIST AR024438A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99202027 1999-06-23

Publications (1)

Publication Number Publication Date
AR024438A1 true AR024438A1 (en) 2002-10-02

Family

ID=8240349

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000103116A AR024438A1 (en) 1999-06-23 2000-06-22 GONADOTROPINE HORMONAL LIBERATING ANTAGONIST

Country Status (6)

Country Link
EP (1) EP1140132A1 (en)
JP (1) JP2003503358A (en)
AR (1) AR024438A1 (en)
AU (1) AU6263800A (en)
CA (1) CA2341974A1 (en)
WO (1) WO2001000227A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1684737A (en) * 2002-06-07 2005-10-19 阿雷斯贸易股份有限公司 Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method
RS54214B2 (en) 2010-09-29 2024-02-29 Ferring Bv Composition for use in treating infertility

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998055470A1 (en) * 1997-06-05 1998-12-10 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
DE69831241T2 (en) * 1997-06-20 2006-03-23 Akzo Nobel N.V. Gonadotropin releasing hormone antagonist

Also Published As

Publication number Publication date
CA2341974A1 (en) 2001-01-04
AU6263800A (en) 2001-01-31
JP2003503358A (en) 2003-01-28
EP1140132A1 (en) 2001-10-10
WO2001000227A1 (en) 2001-01-04

Similar Documents

Publication Publication Date Title
ES2190472T3 (en) TRANSDERMIC PATCH FOR THE ADMINISTRATION OF 17-DEACETIL NORGESTIMATO, ONLY OR IN COMBINATION WITH A STROGEN.
ES2110380T1 (en) METHOD AND EQUIPMENT TO PREVENT THE ERROR'S MALFUNCTION.
DE60327843D1 (en) MEDICAMENT FORMULATIONS WITH DELAYED RELEASE WITH A CARRIER PEPTIDE
AR016798A1 (en) USE OF A LACTOBACILLUS CEPA FOR THE PREPARATION OF A MEDICINAL PRODUCT
ES2173273T3 (en) FABRIC ARTICLE WITH EXTENSION INDICATOR.
ES2137947T3 (en) COMPOSITION AND PROCEDURE FOR SUPPLYING DRUGS.
AR041725A1 (en) PREVENTION, TREATMENT OF SINUCLEINOPATIC DISEASE AND PHARMACOLOGICAL COMPOSITION
PL327146A1 (en) Antagonists of the gonadotrophin liberating hormone
KR890700349A (en) Contraceptive and breast cancer suppression composition and preparation method thereof
BR9913932A (en) Use of glp-1 analogs in the treatment of stroke
CY1104971T1 (en) PREPARATION OF APOINIDOTIDE AND G-CSF AND ITS USE TO STIMULATE HEMAPOPOIETIC PROGENORS
NZ516513A (en) Nitric oxide donors for inducing neurogenesis
DK0994718T3 (en) Gonadotropin releasing hormone antagonist
ITMI922331A1 (en) USE OF PARATORMONE, ITS BIOLOGICALLY ACTIVE FRAGMENTS AND RELATED PEPTIDES, FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS USEFUL IN THE PREVENTION AND THERAPY OF ABORTION AND PRE-TERM BIRTH AND IN GENERAL FOR THE TREATMENT OF THE MANAGEMENT
BR0111506A (en) Macromolecular drug complexes and compositions containing same
BR0010709A (en) Gonadotropins
KR950702120A (en) USE OF PHOSPHONATES FOR THE TREATMENT OF OSTEOPOROSIS
ES2107431T3 (en) AGENTS WITH SELECTIVE ACTION ON ADENOSINE RECEPTORS.
AR024438A1 (en) GONADOTROPINE HORMONAL LIBERATING ANTAGONIST
CL2002001701A1 (en) Use of at least one compound selected from melatonin, melatoninergic agents, melatonin agonists and antagonists, in an amount of 0.0025-50 mg, to prepare a useful medicine for the treatment and improvement of the restorative quality of sleep.
IT9009007A1 (en) 2, 4-DIAMINO-6 PIPERIDINO PIRIMIDINA-3 TOPICAL OXIDE ON THE GLAND IN THE TREATMENT OF ERECTILE IMPOTENCES
ES2152948T3 (en) DERIVATIVES OF IMIDAZOL, TRIAZOL AND TETRAZOL.
EP0788799A3 (en) LHRH-Antagonists in the treatment of fertility disorders
CN205611802U (en) Health male briefs
DE69827017D1 (en) COMBINATIONS OF ENDOMETRIUM-PROTECTING STAGE AND ENDOMETRIUM-ATROPHIZING STAGE WITH ESTROGEN, IN ORAL CONTRACTION PREVENTION